From Weight Loss to Vision Loss: A Potential Risk of Semaglutide
By: Sariah Grant, PharmD Candidate c/o 2027 In June 2021, the Food and Drug Administration approved Novo Nordisk’s semaglutide,…
6th Year Perspective: Behind the Scenes at Pfizer
Featuring: Simkho Shimonov, PharmD Candidate c/o 2025 By: Rebecca Sabzanov, PharmD Candidate c/o 2026 Simkho Shimonov, a dedicated and diligent…
FDA’s New Blueprint for Cell-Based Therapies
By: Reyaz Mussaleen PharmD Candidate c/o 2027 IntroductionThe Food and Drug Administration (FDA) of the United States published a draft…
FDA Accelerated Approval of Enhertu for Broad Treatment of HER2-Positive Solid Cancers
By: Nivaj Haque; PharmD Candidate c/o 2027 In recent years, advancements in oncology have transformed the treatment landscape for various…
Rho Chi Talks: A Look into the St. John’s University Summer Research Program
By: Rosa Kang PharmD Candidate c/o 2027 Summer is a time of endless possibilities. During this time, St. John’s University…
Cystic Fibrosis Therapy Diminishes Hyper-Inflammation In COVID-19-Related Pneumonia
Michelle Flores, Pharm D Candidate c/o 2027 According to clinical trial results from researchers at UCL, UCLH, and the Francis…
An Investigation into the White House Pharmacy
By Holly Nguyen, PharmD Candidate c/o 2024 The White House Medical Unit employs a small confidential team of healthcare professionals,…
Utilization of Tumor Microenvironment in the treatment of Breast Cancer
By: Sameen Siddiqui, PharmD Candidate c/o 2025, Madelyn Lombardo, PharmD Candidate c/o 2027, and Gabriella Lamantea, PharmD Candidate c/o 2027…
Intratumoral and Gut Microbiota Roles in Cancer Treatment
By: Ariella Zadrima, PharmD Candidate c/o 2026 Introduction Cancer is a disease state in which abnormal cells in the body…
E.mbrace the novel E. coli Vaccine
By Ashley Dao, PharmD Candidate c/o 2024 Extraintestinal pathogenic Escherichia coli (ExPEC) is the most common gram-negative bacilli and is…